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Background: The inactivation of c-Jun N-terminal kinase (JNK) is associated with anti-apoptotic and
anti-inflammatory effects in cerebral ischemia, which can be induced by an imbalance between upstream
phosphatases and kinases.
Result: Mitogen-activated protein kinase phosphatase 7 (MKP-7) was upregulated significantly at 4 h of reperfusion
postischemia in rat hippocampi. By administration of cycloheximide or siRNA against mitogen-activated protein
kinase phosphatase 7 (MKP-7) in a rat model of ischemia/reperfusion, an obvious enhancement of JNK activity was
observed in 4 h of reperfusion following ischemia, suggesting MKP-7 was involved in JNK inactivation after
ischemia. The subcellular localization of MKP-7 altered after ischemia, and the inhibition of MKP-7 nuclear export by
Leptomycin B up-regulated JNK activity. Although PI3K/Akt inhibition could block downregulation of JNK activity
through SEK1 and MKK-7 activation, PI3K/Akt activity was not associated with the regulation of JNK by MKP-7.
Conclusions: MKP-7, independently of PI3K/Akt pathway, played a key role in downregulation of JNK activity after
ischemia in the rat hippocampus, and the export of MKP-7 from the nucleus was involved in downregulation of
cytoplasmic JNK activity in response to ischemic stimuli.
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Ischemia/reperfusion brain damage is a major risk factor
of a variety of serious human neurological disorders such
as learning disabilities, cerebral palsy, epilepsy and sei-
zures or even death [1]. c-Jun N-terminal kinase (JNK)
is a potent mediator of inflammation and apoptosis [2].
After ischemia, the JNK signaling pathway is highly acti-
vated, promoting the transcription of ischemia related
genes and ultimately resulting in the lesion and dysfunc-
tion of neurons [3,4]. Blockade of the JNK signaling
pathway has been shown to protect neurons from ische-
mia/reperfusion injury and promote neuronal survival
[5,6]. However, rapid inactivation of JNK following its* Correspondence: Guoj69@yahoo.com.cn
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reproduction in any medium, provided the oractivation by cerebral ischemia has also been observed
[7]. Therefore, studying JNK inactivation may reveal the
mechanism underlying the regulation of JNK activity
after ischemia and support a new approach for treating
ischemia/reperfusion injury.
The JNK signaling cascade is regulated by the balance
between upstream kinases and phosphatases [8]. The
JNK pathway is a mitogen-activated protein kinase
(MAPK) cascade in which mixed lineage kinases (MLKs/
MAPKKK) activate MAP kinase kinase 4/7 (MKK4/7),
which then activate JNK [9]. Inhibiting MLK3 and
MKK4/7 to block upstream kinase cascades involves
JNK inactivation. Akt, known as a neuroprotective pro-
tein, can downregulate JNK activity through blocking an
upsteam kinase [10]. Akt inhibits the ASK1–SEK1–JNK2
signal transduction pathway by inactivating SEK1
through Ser80 phosphorylation in response to glucose
deprivation [11]. It has also been reported that the PI3K/
Akt cascade negatively regulates the JNK pathway in
PC12 cells by inhibiting MLK3 to downregulate MKK-7. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ischemic pre-treatment and estrogen, which is commonly
considered to have a protective role in ischemia induced
injury [13,14].
Phosphatases also regulate JNK activity by direct
dephosphorylation at residues Thr185 and Tyr183 [15].
Members of the MKP family, which includes ten
proteins, dephosphorylate MAPKs at both phospho-
threonine and phosphotyrosine residues simultaneously
within the MAPK TXY (Thr-Xaa-Tyr) activation motif
and share similar structural folding at the catalytic site,
as well as contain critical kinase-interacting motifs
(KIMs) conferring specific MAPK substrate specificity
[16]. Individual MKPs generally show a substrate pre-
ference for one or more of the MAPKs. Among the
MKPs, MKP-7 has a higher substrate specificity for
JNK than for extracellular signal-regulated protein
kinase (ERK) and P38 [17].
Some studies have demonstrated that the RNA inter-
ference (RNAi)-mediated ablation of MKP-7 increases
the extent and duration of JNK activation induced by
H2O2 stimulation in 293 T cells [18,19], while overex-
pression of MKP-7 in COS-7 cells blocks the activation
of JNK in a dose-dependent manner [20]. Just as MAPKs
are regulated by MKPs, in turn MKPs are also regulated
by multiple factors. MKP-7 possesses a long C-terminal
stretch containing both a nuclear export signal (NES)
and a nuclear localization signal (NLS), which mediate
their subcellular localization and nuclear-cytoplasmic
shuttling by transport proteins [20]. Acute oxidative stress
has been reported to lead to redistribution of MKP-7
from the nucleus into the cytoplasm and a reduction
in cytoplasmic p-JNK [21].
In this study, the relationships between upstream
kinases and phosphatases were explored to determine
the key regulator in JNK inactivation following cerebral
ischemia. The findings of this study suggest that MKP-7
plays a key role in JNK inactivation during and after
ischemia, and this regulation occurs independently of
PI3K/Akt pathway.
Results
Dual-phase phosphorylation of JNK induced by cerebral
ischemia coincides with Akt-induced SEK1 and MKK-7
phosphorylation in the rat hippocampus
It is well known that cerebral ischemia highly induces
activation of the JNK pathway through phosphorylation,
leading to apoptosis and dysfunction of neurons. How-
ever, JNK activity has been observed to obviously de-
crease following its activation by cerebral ischemia [7],
but the precise mechanism remains unclear. To deter-
mine the underlying cause of the abrupt JNK inactiva-
tion following cerebral ischemia, phosphorylation of JNK
at Thr183/Tyr185 and its upstream molecules Akt atSer473, SEK1 at Ser80 and MKK-7 at Ser 271/Thr275
were examined in the rat hippocampus following ische-
mia. Rats were subjected to four-vessel occlusion, with 10
min of ischemia followed by reperfusion for 15 min, 1, 2,
4, 6 and 24 h. As shown in Figure 1A, phosphorylation of
JNK showed a biphasic pattern of elevation during reper-
fusion, gradually increasing from 15 min (P < 0.05),
peaking at 1 h (P < 0.05), but then decreasing significantly
at 4 h (P < 0.05) before elevating again at 24 h (P < 0.05).
Meanwhile, the phosphorylation of Akt, SEK1 and MKK-7
peaked at 1 h (P < 0.05), showing that phosphorylation of
these proteins may be associated with JNK. After
peaking at 1 h, their phosphorylation sharply decreased at
4 h (P < 0.05) and was elevated again after 24 h (P < 0.05).
Meanwhile, no changes were observed in the levels of
total JNK, Akt, SEK1, MKK-7 and β-actin in each group
during the reperfusion (P > 0.05, Figure 1). These results
demonstrated that cerebral ischemia induced the dual-
phase phosphorylation of JNK, and the phosphorylation
patterns of Akt, SEK1 and MKK-7 showed the same
trends as that of JNK after ischemia.
PI3K/Akt inhibitor LY294002 increases SEK1 and MKK-7
activities but does not result in upregulation of JNK
activity following cerebral ischemia
The results above showed that Akt phosphorylation
was associated with the JNK signaling cascade. How-
ever, to determine the exact role played by Akt in the
JNK cascade in cerebral ischemia, the inhibitor
LY294002 (LY) was employed to block the PI3K/Akt
pathway. Rats underwent four-vessel occlusion and
endured a 10-min period of ischemia, followed by
reperfusion for 1 h. Phospho-specific antibodies were
employed, and changes in JNK, Akt, SEK1 and MKK-7
activities were examined in the hippocampus of rats
after the administration of LY or vehicle. The inacti-
vated form of SEK1 is phosphorylated at Ser80, while
the activated form of MKK7 is phosphorylated at Ser
271/Thr275. As shown in Figure 1B, in the 1-h reper-
fusion groups, a significant decline of p-Akt (Ser473)
and p-SEK1 (Ser80) was observed in those rats trea-
ted with the LY compared with the vehicle-treated
rats (P < 0.05). Meanwhile, the level of p-MKK-7
(Ser271/Thr275) was significantly elevated in the LY
group compared with the vehicle group. However, the
levels of activated JNK differed little between the 1-h
reperfusion groups with and without the administra-
tion of LY. This result suggests that the PI3K/Akt
inhibitor LY could downregulate Akt activity following
cerebral ischemia, which increased the activity of
SEK1 and MKK-7 but did not lead to the elevation
JNK activity. Therefore, we hypothesized that another
mechanism must be involved in JNK inactivation at 1
h reperfusion postischemia.
Figure 1 Western blot analysis of JNK, Akt, SEK1 and MKK-7 activities in response to ischemia at different times after reperfusion and
effect of PI3K/Akt inhibitor LY294002 after 1 h of reperfusion. Proteins were extracted and measured using antibodies against p-JNK
(Thr183/Tyr185), p-Akt (Ser473), p-MKK-7 (Ser271/Thr275), p-SEK1 (Ser80), JNK, Akt, MKK-7 and SEK1. A: Phosphorylation state of JNK, Akt, MKK-7
and SEK1 after different reperfusion times (15 min, 1, 2, 4, 6 and 24 h) following 10 min of ischemia. B: Determination of p-JNK, p-MKK-7 and p-
SEK1 levels in animals administered LY294002 (LY) compared with sham and control groups (vehicle, Veh). ODs are presented as means ± SEM
(n = 4) and expressed as magnitudes of change versus sham control or control. *P < 0.05. versus sham control; #P < 0.05, comparison between the
1-h chemically treated reperfusion groups and their respective vehicle controls.
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following cerebral ischemia
Activated JNK promotes ischemic injury related protein
expression through phosphorylation of transcription fac-
tors such as c-jun. In order to control appropriate gene
transcription, the activity of JNK must be tightly regu-
lated by the actions coordinated between protein kinases
and phosphatases. MKPs comprise a subset of protein
tyrosine phosphatases, which can dephosphorylate both
phosphothreonine and phosphotyrosine residues. Cyclo-
heximide (CHX) is usually considered a protein synthesis
inhibitor, and some studies have also shown that it caninhibit the activity of MKPs [22]. To explore whether
MKPs were involved in JNK inactivation after ischemia in
the rats, CHX was employed in this study. As shown in
Figure 2A, levels of JNK activity were significantly elevated
in the CHX group compared with the vehicle group at 4 h
after reperfusion (P < 0.05). BCI, an allosteric inhibitor of
Dusp6 [23], was also used in this study, however, the levels
of JNK activity were not changed in the BCI group com-
pared with the vehicle group at 4 h after reperfusion
(Figure 2B, P > 0.05). Furthermore, activated JNK levels
differed little between the 24-h reperfusion groups with
and without the administration of MKPs inhibitor (CHX
Figure 2 Effect of CHX or BCI on p-JNK in rat hippocampi following ischemia/reperfusion. Proteins were extracted and measured using
antibodies against p-JNK (Thr183/Tyr185) and JNK. A: Effect of CHX on p-JNK (Thr183/Tyr185) during 4 h or 24 h of reperfusion following 10 min
of ischemia. B: Effect of BCI on p-JNK after 4 h and 24 h of reperfusion following ischemia. OD data are presented as means ± SEM (n = 4) and
expressed as magnitudes of the alteration versus sham control or control. *P < 0.05. versus sham control; # P < 0.05, comparison between the
chemically treated 4-h and 24-h reperfusion groups and their vehicle control.
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This result suggested that a few MKPs but not Dusp6
were involved in JNK inactivation at 4 h reperfusion after
ischemia.
MKP-7 participates in JNK inactivation in the rat
hippocampus after cerebral ischemia
We wanted to further identify which member of the
MKP family was involved in the downregulation of
JNK activity at 4 h after reperfusion. MKP-7 is a
JNK-specific phosphatase. A previous study showed
that the level of JNK phosphorylation is significantly
prolonged when the expression of endogenous MKP-7
is ablated by siRNA [18,19]. In order to explore the role of
MKP-7 in JNK inactivation after ischemia, its cytoplasmic
level and activity were observed after ischemia/reper-
fusion. As shown in Figure 3A, the levels of cytoplas-
mic MKP-7 reached peak levels at 4 h (P < 0.05).
However, it decreased obviously at 24 h again (P < 0.05).
This result showed that the trend of cytoplasmic MKP-7
protein level followed the opposite pattern as that of JNK
activity after ischemia. As shown in Figure 3B, MKP-
7 activity after ischemia was also observed to slightly
increase from 15 min to 2 h (P < 0.05) and reached a
peak level at 4 h (P < 0.05). However, it decreased
significantly at 24 h (P < 0.05). The trend in MKP-7
activity was similar to that of the correspondingcytoplasmic protein level and again displayed the opposite
pattern to that of JNK activity.
The results presented above indicated that MKP-7 could
participate in the inhibition of JNK activity after ischemia.
To further clarify the role of MKP-7 in down-regulation of
JNK activity after ischemia, MKP-7 siRNA was employed
to decrease the amount of cytoplasmic MKP-7. As shown
in Figure 4, JNK activity was markedly reduced in the 4-h
reperfusion control and 4-h reperfusion vehicle groups
compared with that in the 1-h reperfusion control. As
expected, this inhibitory effect was sufficiently relieved
after 4 h of reperfusion regardless of MKP-7 siRNA treat-
ment. However, in contrast with the changes in p-JNK, this
phosphorylation state was maintained after 24 h of reperfu-
sion, and administration of MKP-7 siRNA was unable to
reverse it (P > 0.05). This result confirmed our hypothesis
that MKP-7 was involved in JNK inactivation during the 4
h but not 24 h of reperfusion post-ischemia.
Ischemia/reperfusion induces MKP-7 nuclear export to
downregulate JNK activity
The results above showed that ischemia/reperfusion
elevated the levels and activities of cytoplasmic MKP-7
to downregulate JNK activity at 4 h of reperfusion after
ischemia. The next step was to investigate the potential
mechanism of MKP-7 upregulation after ischemia.
MKP-7 contains an intrinsic NES motif which mediates
Figure 3 Temporal curve of MKP-7 protein levels and activities
during different reperfusion times following cerebral ischemia.
Proteins were extracted and measured using antibodies against
MKP-7. MKP-7 was purified by immunoprecipitation, and its activity
was measured using an alkaline phosphatase assay. A: Time curve of
MKP-7 levels during different reperfusion times (15 min, 1, 2, 4, 6
and 24 h) following 10 min of ischemia. B: Temporal curve of MKP-7
activity after different reperfusion times (15 min, 1, 2, 4, 6 and 24 h)
following 10 min of ischemia. OD data are presented as means ±
SEM (n = 4) and expressed as magnitudes of the alteration versus
sham control or control [*P < 0.05 versus sham control].
Figure 4 Effect of administration MKP-7 siRNA on the
phosphorylation state of JNK (Thr183/Tyr185) after 4 or 24 h of
reperfusion post-ischemia. Non-coding (NC) siRNA was used as a
control. Proteins were extracted and measured using antibodies
against p-JNK (Thr183/Tyr185), JNK and MKP-7 A: Determination of
p-JNK (Thr183/Tyr185) and MKP-7 levels with and without MKP-7
siRNA after 1 or 4 h of reperfusion following 10 min of ischemia. OD
data are presented as means ± SEM (n = 4) and expressed as
magnitudes of the alteration versus sham control or control. *P <
0.05, versus sham control; #P < 0.05, comparison between chemically
treated 4-h and 24-h reperfusion groups and their vehicle control.
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tion as a nuclear-cytoplasmic shuttle protein upon
stimulation by extracellular signals. To explore whether
MKP-7 subcellular localization was altered during ische-
mia/reperfusion, the cytoplasmic and nuclear levels of
MKP-7 were examined by western blot. As shown in
Figure 5A, there was a striking increase in cytoplasmic
MKP-7 and a decrease in nuclear MKP-7 in the 4-h
reperfusion group compared with the sham group. How-
ever, cytoplasmic MKP-7 obviously decreased, while
nuclear MKP-7 was strikingly elevated after 24 h of
reperfusion. The results above suggested that MKP-7
was transported from the nucleus to cytoplasm at 4 h of
reperfusion and was imported back to the nucleus at 24
h of reperfusion after ischemia.
As it was demonstrated above that nuclear export of
MKP-7 increased its cytoplasmic levels at 4 h of reperfu-
sion after ischemia, we further examined whether thisexport of MKP-7 was involved in JNK inactivation.
LMB, a specific inhibitor of nuclear export that blocks
binding between the NES and export receptor, causes
nuclear accumulation of MKP-7 [21]. In this study, LMB
was employed to identify the relationship between MKP-7
export and down-regulation of JNK activity. As shown in
Figure 5B, there was a striking decrease in cytoplasmic
MKP-7 and an increase in nuclear MKP-7 in the LMB
group after 4 h of reperfusion. Meanwhile, as expected,
the levels of JNK activity increased in the LMB group
compared with the vehicle group. These results suggested
that the export of MKP-7 was involved in JNK inactivation
after 4 h of reperfusion after ischemia.
Ischemia-induced activation of MKP-7 is independent of
the PI3K/Akt pathway
We also found that treatment with the PI3K/Akt inhibi-
tor LY294002 induced a significant elevation in JNK
activity during the 4 h of reperfusion (Figure 6A).
Although there is much evidence to support the conten-
tion that JNK dephosphorylation/inactivation by MKP-7
is independent of PI3K/Akt pathway, some studies have
Figure 5 Western blot analysis of the localization of MKP-7 in cytoplasm and nucleus after ischemia and the effect of inhibition of this
MKP-7 translocation by LMB on JNK activity. LMB administered in rat hippocampus as described in the Methods, and its vehicle (Veh) was
used as a control. Proteins were obtained from the cytoplasm and nucleus and measured using antibodies against p-JNK (Thr183/Tyr185) and
MKP-7. A: MKP-7 levels in cytoplasm and nucleus after 4 or 24 h of reperfusion following 10 min of ischemia. B: Effect of LMB on JNK activity in
cytoplasm and levels of MKP-7 in cytoplasm and nucleus after 4 h of reperfusion post-ischemia. OD data are presented as means ± SEM (n = 4)
and expressed as magnitudes of the alteration versus sham control or control. *P < 0.05, versus sham control; # P < 0.05, comparison between
chemically treated 4-h reperfusion groups and their vehicle control.
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downregulation of JNK activity [12,24]. Furthermore,
whether PI3K/Akt pathway downregulates JNK via
MKP-7 was previously unknown. In order to identify the
relationship between inactivation of JNK by MKPs and
the PI3K/Akt signaling pathway, the level and activity of
MKP-7 were examined by administration of the PI3K/
Akt inhibitor LY294002 (LY). As shown in Figure 6B,
there was no difference between the LY and vehicle
groups in terms of MKP-7 activity during the 4-h reper-
fusion. Meanwhile, the level of MKP-7 also differed little
between the 4-h reperfusion groups with and without
the administration of LY, both exhibiting high levels
(Figure 6C). Furthermore, the protein level and activity
of JNK and MKP-7 kept stable between the sham groups
with and without the administration of LY. These results
suggested that the MKP-7 downregulation of JNK
activity after ischemia did not depend on the PI3K/Akt
pathway.Discussion
Nerve cells involved in ischemia/reperfusion injury acti-
vate a complex system of signal transductions, in which
activation of JNK plays an important role in cerebral le-
sion. Inactivation of JNK blocks phosphorylation of a wide
range of transcription factors and decreases the expression
of ischemia related proteins [25]. Therefore, the thera-
peutic potential of JNK inhibition is being investigated as
an approach to protect cells from neurodegeneration and
dysfunction [26].
Akt is an important cellular survival protein that pro-
tects cells from damage by inactivating JNK [27]. During
ischemia/reperfusion, ischemic pre-conditioning and
estrogen may activate Akt to protect neurons by down-
regulating JNK activity. Therefore, Akt is considered an
important negative regulator of JNK activity [28]. How-
ever, in the current study, the evolution of Akt activity
at 1 h of reperfusion did not result in JNK inactivation
after ischemia and downregulation of Akt activity by
Figure 6 Determination of JNK and Akt activities with and without LY294002 (LY) after 4 h of reperfusion after ischemia and effect of
LY on the level and activity of MKP-7 after 4 h of reperfusion. A. Effect of LY on Akt and JNK activities after 4 h of reperfusion. B. Effect of LY
treatment on MKP-7 level after 4 h of reperfusion. C. Effect of LY treatment on MKP-7 activity after 4 h of reperfusion. ODs are presented as
means ± SEMs (n = 4) and expressed as magnitudes of change versus sham control. *P < 0.05, versus sham control, # P < 0.05, comparison
between chemically treated 4-h reperfusion groups and their vehicle control.
Zhu et al. BMC Neuroscience 2013, 14:1 Page 7 of 11
http://www.biomedcentral.com/1471-2202/14/1PI3K/Akt inhibitor also did not induce increment of
JNK activity at 1 h reperfusion. On the other hand,
increases in the activity and level of MKP-7 at 4 h of
reperfusion were observed and associated with JNK
inactivation. Therefore, we propose that MKP-7 is an
important newly defined regulator in the downregulation
of JNK activity after ischemia.
The MKP-7 involves in the downregulation of JNK
activity after ischemia in a PI3K/Akt independent manner.
So it could be supposed that there are some differences
between MKP-7 and Akt in their protective roles through
JNK inactivation after ischemia. The increase of Aktactivity to block the JNK cascade after ischemia is induced
by external stimuli such as estrogen, anesthetic pre-
conditioning and ischemic pre-conditioning [13,29,30].
However, the elevations in MKP-7 level and activity to in-
activate JNK are induced by ischemia/reperfusion and not
by other protective factors [31]. In contrast to the protec-
tion mechanism of Akt, the inhibition of JNK by MKP-7
provides a negative feedback regulatory mechanism
which prevents excessive ischemia/reperfusion injury after
ischemia. Essentially, ischemia/reperfusion induces a series
of alterations in physiological conditions and activates the
JNK signal cascade. Meanwhile, it also elevates the level
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inhibit JNK activity by direct dephosphorylation. While
blockade of the JNK cascade induced by Akt is long-
lasting and can alleviate ischemia/reperfusion injury [24],
the administration of siRNA to specifically target MKP-7
showed no effect on JNK activity after 24 h of reperfusion.
These results suggested that the inactivation of JNK by
MKP-7 did not last throughout the 24 h after reperfusion.
Therefore, the protective effect of MKP-7 may have
been short-lived and could not substantially alleviate
ischemia/reperfusion injury following cerebral ischemia.
The regulation of phosphatases can usually be observed
as a change in protein levels, phosphatase activity and
stabilization. Elevation of MKP-7 mRNA by serum has
been shown to result in the increase of the MKP-7 protein
level [32]. However, in this study, we found other regula-
tory mechanisms which elevated MKP levels. MKP-7 is a
shuttle protein, and the exclusion of JNK-specific MKP-7
from the nucleus and its accumulation in the cytoplasm
showed that it was exported from the nucleus after
ischemia in the rat hippocampus. Since MKP-7 is a
specific phosphatase of JNK, the change of its subcellular
localization could have altered the level of p-JNK.
Therefore, it is reasonable to conclude that the elevation
of cytoplasmic MKP-7 after export from the nucleus
ultimately led to the downregulation of JNK activity. ThisFigure 7 Model of JNK inhibition after cerebral ischemia/reperfusion.
be downregulated by dephosphorylation of JNK at Thr183/Tyr185 by speci
is increased by its nuclear-to-cytoplasmic translocation, which ultimately in
phosphorylation Ser80 and inhibits MKK-7 by MLK3 phosphorylation at Ser
after ischemia in the rat hippocampus.novel observation suggested that the altered subcellular
localization of MKPs also led to the elevation of
cytoplasmic MKP levels.
Conclusions
In summary, MKP-7 was demonstrated in this study to
play key roles in JNK inactivation during cerebral ischemia,
and this inhibition of JNK occurred independently of
PI3K/Akt pathway. Shuttling of MKP-7 was shown to be
exported from the nucleus to downregulate cytoplasmic
JNK activity after ischemia (Figure 7). These findings
enrich our understanding of the mechanism of JNK inacti-
vation after ischemia. Thus, exploring drugs which can
elevate MKP activity and duration may provide new targets
for treatment of ischemia/reperfusion injury.
Methods
Surgical procedure
Animal surgery was performed in compliance with the
Institutional Animal Care and Use Committee, conforming
to international guidelines on the ethical use of animals,
and was approved by the Biological Research Ethics
Committee of Nanjing Medical University (permit number:
NYLL2010-0009). Every effort was made to minimize the
number of animals used and their suffering. Adult male
Sprague–Dawley rats weighing 250–300 g (obtained fromJNK activity can be elevated by activated ASK-SEK1 or MLK3-MKK-7, or
fic phosphatases MKP-7 following ischemia/reperfusion. MKP-7 function
hibits JNK activity. Active Akt (which inactivates SEK1 by
674) does not affect down-regulation of JNK activity induced by MKP-7
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University) were maintained at room temperature and
given free access to food and water. Before surgery, the
animals were deprived of food overnight. The rats were
anesthetized by intraperitoneal injection of 20% chloral
hydrate (250 mg/kg) and surgically prepared for four-
vessel occlusion according to the method described by
Pulsinelli et al. [33]. Bilateral vertebral arteries were elec-
trocauterized, and both common carotid arteries were
dissected free. Twenty-four hours later, both common
carotids were occluded with aneurysm clips. Rats were
kept awake during the periods of ischemia and subsequent
reperfusion, which eliminated the potential effects of
sedatives such as chloral hydrate on the results of the
experiment. The selected rats matched the following
criteria: maintenance of dilated pupils, loss of cornea
reflex, completely flat electroencephalogram, rigor of the
extremities and vertebral column, and maintenance of rec-
tal temperature at approximately 37°C. Rats in the sham
group received the same surgical procedures except for
the occlusion of the four arteries.Infusion and administration of drugs
The phosphoinositide-3 kinase (PI3K)/Akt inhibitor
LY294002 (LY, 10 mM, Calbiochem-Novabiochem Corp.,
San Diego, CA, USA), MAPK phosphatase or protein
synthesis inhibitor cycloheximide (CHX, 177 mM,
Sigma-Aldrich, St. Louis, MO, USA), the Dusp6 inhibi-
tor (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-
1H-inden-1-one (BCI, 28 mM, Sigma-Aldrich Co.) and
MKP-7 nuclear export inhibitor Leptomycin B (LMB,
0.2 μg/μl, Enzo Life Sciences, Farmington, NY, USA) or
the same volume of vehicle (2 μL) were injected into the
cerebral ventricle (0.8 mm posterior and 1.5 mm lateral
to the bregma; 3.5 mm deep) using a micro-injector 30
min before ischemia induction according to previous
previously published reports [34,35]. The injector was
retained in place for another 5 min after the injection,
avoiding any possible backflow of liquid along with the
injection void.In vivo MKP-7 siRNA transfer
Five microliters of MKP-7 siRNA (20 μM, RiboBio Co.,
Guangzhou, China) or control siRNA-A (20 μM, RiboBio)
was diluted with the same volume of transfection reagent
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). After
gently pipetting the solution up and down, the mixture
was then incubated for 45 min at room temperature
(~25°C) and injected into the cerebral ventricle (0.8 mm
posterior and 1.5 mm lateral to the bregma; 3.5 mm deep)
using a micro-injector. This injection was repeated
four times, every 12 h starting 2 days before ischemia
induction [36].Tissue sample preparation
Rats were sacrificed by decapitation at various times: 10
min after ischemia and 15 min, 1, 2, 4, 6 and 24 h after
reperfusion. The hippocampal tissues were removed on ice
and homogenized in 1:10 (W/V) ice-cold homogenization
buffer A [50 mM HEPES (pH 7.4), 100 mM KCL, 1 mM
Na3VO4, 50 mM NaF and 1 mM PMSF] containing 1%
mammalian proteinase inhibitor cocktail (Sigma-Aldrich).
Proteins in the cytoplasm and membrane were extracted
after centrifugation at 800 × g and 4°C. After this step, the
supernatant was centrifuged at 14,000 × g and 4°C to
harvest cytoplasmic proteins. The resulting pellet after the
first centrifugation was resuspended in homogenization
buffer B [50 mM HEPES (pH7.4), 100 mM KCL, 1 mM
Na3VO4, 50 mM NaF, 1 mM PMSF, 1 mM DTT, 1% cock-
tail, and 5% SDS] and kept on ice for 30 min, followed by
ultrasonic disruption for 6 s, repeated 6 times and then
centrifugation at 14,000 × g and 4°C. The supernatants
containing the nuclear or cytoplasmic proteins were
extracted and then stored at −80°C until assayed. The
protein concentrations of the extracts were deter-
mined according to the Bradford method using bovine
serum albumin (BSA) as a standard [37].
Western blot
Denatured samples were separated by 10% SDS-PAGE
and electrotransferred onto nitrocellulose membranes
(NC, pore size, 0.2 μm). The proteins on the membrane
were probed with primary antibodies against JNK, phos-
phorylated JNK at Thr183/Tyr185, Akt, phosphorylated
Akt at Ser473, phosphorylated SEK1 at Ser80, phos-
phorylated MKK7 at Ser271/Thr275, MKP-7 (Santa
Cruz Biotechnology) and β-actin (Boster Biotechnology,
WuHan, HB, China) at 4°C overnight. Following three
5–10 min washes in Tris-buffered saline, 0.1% Tween-20
(TBST), the immune complexes on the membrane
were then incubation with horseradish peroxidase
(HRP)-conjugated anti-rabbit or mouse secondary anti-
body (1:5000, ZhongShan Golden Bridge Biotechnology,
Peking, China) for 2 h. Following the incubation, the
membranes were then washed in TBST three times for 10
min each time. The bands on the membranes were
scanned and analyzed using an image analyzer.
Phosphatase activity assay
The primary rabbit antibody to MKP-7 (1–2 μg) was
added to each sample of total proteins (200 μl). After
shaking overnight at 4°C, protein A/G PLUS-Agarose
(10 μl, Santa Cruz Biotechnology) was added and incu-
bated with shaking for 2 h at 4°C. The protein A/G
PLUS-Agarose was precipitated by centrifugation at
5000 × g and washed three times with immunoprecipita-
tion buffer. The washed agarose was resuspended in 200
μl phosphatase assay buffer containing 20 mM pNPP
Zhu et al. BMC Neuroscience 2013, 14:1 Page 10 of 11
http://www.biomedcentral.com/1471-2202/14/1and 50 mM imidazole (pH 7.5) (both from Enzo Life
Sciences, Farmington, NY, USA) and incubated for 2 h
at 30°C. The reaction was stopped by the addition of 800
μl of 0.25 N NaOH, and p-NPP hydrolysis was measured
by absorbance at 410 nm.
Data and statistical analysis
Data were documented as means ± SD from at least three
independent rats. One-way analysis of variance (ANOVA)
followed by Duncan’s new multiple range method was
applied to analyze the statistical results. P-values < 0.05
were considered significant.
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